Covalon Technologies Appoints Interim CEO

Covalon Technologies Ltd. has appointed Board Chairman Amir Boloor as interim CEO to replace Brian Pedlar as the company searches for a permanent surrogate.
 
With Boloor taking on an executive role, the board has named Joseph Cordiano as lead independent director.
 
“As an experienced CEO, and member of Covalon’s board since 2020, Amir has a deep understanding of Covalon and its strategy and is well-placed as interim CEO to oversee the continued execution of the company’s strategy as it commences a search for a new CEO,” said board member Martin Goldfarb, one of Covalon’s largest shareholders.

“I look forward to the opportunity to serve in this role while the board conducts a search for Covalon’s next CEO,” Boloor stated. “I am looking forward to partnering with Covalon’s leadership team to ensure we continue to execute on behalf of all our stakeholders, including our clients, our staff and our shareholders. Covalon has a strong balance sheet, no debt, a dedicated and experienced team, a large portfolio of patented healthcare technologies and significant momentum with its advanced wound care and infection prevention product portfolios.”

Pedlar will remain on Covalon’s Board of Directors. “On behalf of the entire Board, I would like to sincerely thank Brian for his leadership during his more than 13-year tenure, including the company’s evolution from a research and development-centric company to a product-centric company. He set the stage for Covalon’s next phase of growth,” Boloor said. “We look forward to receiving his continued advice and wish him much success in his future endeavors.”
 
Covalon Technologies Ltd. is a patient-driven medical device company with a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings. The company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: by developing products sold under Covalon’s name; and developing and commercializing medical products for other medical companies under development and license contracts. The company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF.